Compare Amphastar Pharmaceuticals Inc (AMPH) vs HP Inc (HPQ) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

HPQ trades at $24.22, up 0.37% today, with a bullish technical outlook and strong recent earnings beats. The stock shows attractive valuation with a P/E of 8.97 and P/S of 0.4, supported by consistent operating cash flow of $3.7B in 2025. Recent news highlights HP's AI PC partnerships and dividend yield near 5%, though revenue growth remains modest amid industry headwinds.

Outlook is cautiously positive given low valuation and dividend appeal, but risks include PC market volatility and competitive pressures. Analyst consensus is mixed with a $22 price target below current levels, suggesting limited near-term upside despite fundamental strength.